Molecular targeted therapy: Treating cancer with specificity

By Yeuan Ting Lee, Y. Tan, C. Oon. European Journal of Pharmacology, 2018

882 citations recorded by the source corpus.

ABSTRACT Molecular targeted therapies are revolutionized therapeutics which interfere with specific molecules to block cancer growth, progression, and metastasis. Many molecular targeted therapies approved by the Food and Drug Administration (FDA), have demonstrated remarkable clinical success in the treatment of a myriad of cancer types including breast, leukemia, colorectal, lung, and ovarian cancers. This review provides an update on the different types of molecular targeted therapies used in the treatment of cancer, focusing on the fundamentals of molecular targeted therapy, its mode of action in cancer treatment, as well as its advantages and limitations.

Subfields: Molecular Biology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/eff7fd1e67ca186eff17a699e8d91e33afd7d5cd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Shi
2. Shijun Li
3. Zhiwen Fu
4. Yu Zhang
5. Sifei Han

Citations in the corpus

• Antibody drug conjugate: the “biological missile” for targeted cancer therapy (2022, background): “Compared with wild-type proteins, mutant proteins usually have higher ubiquitination level and are easier to be internalized and degraded.(269) It means that if ADC is used to target mutant proteins, it may bring significant clinical response.”